Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of “Moderate Buy” from Analysts
by Renee Jackson · The Cerbat GemShares of Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the thirteen analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $37.8889.
A number of research firms have recently commented on ZYME. Stifel Nicolaus upped their target price on Zymeworks from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Leerink Partners upped their target price on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a research note on Tuesday, March 3rd. HC Wainwright upped their target price on Zymeworks from $32.00 to $46.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research note on Monday, April 20th.
Get Our Latest Stock Analysis on ZYME
Zymeworks Price Performance
Shares of NASDAQ ZYME opened at $28.56 on Thursday. The business’s 50 day moving average is $25.11 and its two-hundred day moving average is $23.68. Zymeworks has a 1-year low of $10.86 and a 1-year high of $29.75. The stock has a market capitalization of $2.11 billion, a P/E ratio of -26.44 and a beta of 1.20.
Zymeworks (NASDAQ:ZYME – Get Free Report) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.55) earnings per share for the quarter. Zymeworks had a negative return on equity of 26.00% and a negative net margin of 76.56%.The company had revenue of $2.52 million for the quarter. As a group, equities research analysts anticipate that Zymeworks will post 0.97 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Capricorn Fund Managers Ltd bought a new position in shares of Zymeworks during the fourth quarter valued at approximately $26,931,000. Dana Investment Advisors Inc. bought a new position in shares of Zymeworks during the fourth quarter valued at approximately $1,272,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of Zymeworks in the fourth quarter valued at approximately $264,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Zymeworks by 7.8% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 32,815 shares of the company’s stock valued at $864,000 after purchasing an additional 2,383 shares during the period. Finally, Kornitzer Capital Management Inc. KS purchased a new stake in shares of Zymeworks in the fourth quarter valued at approximately $2,338,000. Institutional investors own 92.89% of the company’s stock.
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.
At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.